摘要
Objective:To evaluate the prevalence of Candida species in cancer patients with candidemia around the world,and to identify related risk factors and their antifungal resistance,with an emphasis on non-albicans Candida species(NACs).Methods:The published papers related to the subject were systematically searched in databases of MEDLINE(including PubMed),Web of Science,Scopus,Science Direct,and Google Scholar between the 1st January 2000 and 21st April 2021.Results:Among the 4546 records,69 studies met the inclusion criteria.The pooled prevalence of NACs in cancer patients with candidemia was 62%(95%CI 58%-67%;I2=94.85%,P=0.00).Based on type of cancer,the pooled prevalence of NACs in hematologic and solid cancer patients were 68%(95%CI 65%-70%)and 52%(95%CI 49%-54%),respectively.Among NACs,Candida(C.)parapsilosis was the most frequently isolated organism followed by C.tropicalis and C.glabrata.In addition,the therapeutic usage of antibiotics was found as the most common risk factor,accounting for 85%(95%CI 81%-89%)and central venous catheter accounting for 69%(95%CI 62%-77%).Conclusions:The incidence of Candida bloodstream infections among cancer patients is a growing concern,especially when the etiologic agents of candidemia tend to shift towards NACs.
